However, with the publication of the recent ADA guidelines, GLP-1 RAs are now recommended for the first time as an adjunctive therapy to lifestyle interventions for adults with T2D, particularly those who are overweight or obese and have NAFLD/MASLD (Level of evidence B). The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatotic liver disease.